Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2021-04-28 Regulatory Filings
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약 체결) between Pharmicell and Thermo Fisher Scientific. It details the contract value, duration, and counterparty. Since this is a specific regulatory disclosure of a business contract that does not fit into the other specialized categories like M&A or financial reports, it falls under the general regulatory filing category.
2021-04-28 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Changes in Shareholding by Major Shareholders and Others' (최대주주등소유주식변동신고서) from Pharmicell Co., Ltd. It details specific transactions by company executives and major shareholders, including the name of the individual (Jung Gil-soo), the change in share count, and the relationship to the company. This falls under the category of Director's Dealing (DIRS) as it reports personal share transactions by company insiders.
2021-04-02 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Meeting of Shareholders (AGM) for the company Pharmicell, dated 2021-03-24. It details the approval of financial statements, election of directors, and other resolutions passed during the meeting. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements.
2021-03-24 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is titled '감사보고서 제출' (Submission of Audit Report) and provides a summary of the audit opinion, financial data, and auditor information for the fiscal year 2020. It is a regulatory filing submitted to the KRX (Korea Exchange) to announce the completion and submission of the audit report. Since it is a standalone report regarding audit results and financial statements, it falls under the Audit Report category. FY 2020
2021-03-16 Korean
사업보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Pharmicell Co., Ltd. for the fiscal year 2020. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. While it contains financial data, it is the formal audit report required by law, not a standalone financial supplement or a quarterly report. Therefore, it is classified as an Audit Report. FY 2020
2021-03-16 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and explicitly mentions '정정신고' (Correction Report) regarding a proxy solicitation for a general meeting of shareholders. It contains information about the company's financial statements, board proposals, and instructions for shareholders to exercise their voting rights via proxy or electronic voting. This aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2021-03-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.